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IL-1 is a polypeptide hormone produced primarily by activated monocytes (1, 2).
Two forms ofIL-1, IL-la and IL-1ß, have been identified, cloned, and shown to have
similar biological properties (2). IL-1 is an immunoregulator and a mediator ofinflam-
mation (1, 2). Among its notable inflammatory properties are the ability to stimu-
late fibroblast (3) and smooth muscle cell (4) proliferation, to activate the produc-
tion of both collagenase and collagen by fibroblasts and synovial cells (1, 2), and
to induce the production of other mediators of inflammation such as IL-6, platelet
activating factor (PAF) (2), and platelet-derived growth factor (PDGF) (5). Thus,
IL-1 plays a role in mesenchimal tissue remodeling by affecting both the destructive
and the reparative processes of connective tissue.
Tobacco glycoprotein (TGP) is a glycoprotein derived from tobacco, which is rich
in polyphenols (6). TGP elicits an immediate IgE-mediated wheal and flare response
in one-third of human volunteers (6), and induces a preferential IgE response in
experimental animals (7). TGP stimulates proliferation of human T cells and differen-
tiation of human B cells into Ig-secreting cells (8). It also activates factor XII-de-
pendent pathways, leading to kinin generation (9) . The multifaceted effects of TGP
suggested the possibility that it might exert some of its effects by inducing IL-1 produc-
tion. Here we report that human leukocytes cultured with TGP produce both IL-la
and IL-1ß, and that two peaks of synthesis are observed. Thus, IL-1 production by
human leukocytes exposed to TGP might be one of the cellular mechanisms under-
lying the pathological sequelae of cigarette smoking.
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Materials and Methods
BriefDefinitive Report
Subjects.
￿
This study was approved by The New York Hospital-Cornell University Med-
ical Center Committee on Human Rights in Research. PBL were isolated by Ficoll-Hypaque
density centrifugation of heparinized blood (8) from healthy volunteers and from leukocyte
concentrations obtained from The Greater New York Blood Center.
7-UP
￿
TGP was isolated from cured tobacco leaves as previously described (6, 10).
Induction of IL-1 Production.
￿
PBL were cultured at 2.5 x 106 cells/ml medium with or
without TGP as previously described (8). Supernatants were collected at various times and
kept frozen. To obtain supernatants from adherent cells, PBL at 2.5 x 106 cells/well (24-well
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cluster) were pre-incubated for 1-2 h at 37°C in medium containing 2.5% FCS. Thenonad-
herent cells were aspirated, and the adherent cells were cultured with 0.5 ml medium with
or without TGP.
IL-1 Assay.
￿
The thymocyte costimulation assay was used (11). The results are presented
as either mean cpmoftriplicate wellsor as units, calculated by probit anlaysis usingmonocyte-
derived IL-1 as a standard. (100 U/ml) (Genzyme, Boston, MA) (12).
MIL-1 andAntibodies to IL-1.
￿
rhIL-la and antibodies to rhIL-la were gifts of Drs. Peter
T. Lomedico and Richard Chizzonite, respectively (Hoffman-La Roche, Inc., Nutley, NJ).
rhIL-10 and rabbit polyclonal antibody to rhIL-1/3 were giftsfrom Dr. Philip Simon (Smith,
Klineand French, Philadelphia, PA). Rabbit polyclonal antibodies to IL-1(a and /3)waspur-
chased from Genzyme. Rabbit anti-rhIL-1a was also purchased from Cistron Biotechnology
(Pine Brook, NJ).
Isoelectric Focusing(IEF).
￿
IEF was carried out in tubescontaining 1.5% agarose, 10% sor-
bitol, and ampholines (2 .6%, pH 3.5-10 and 1.3% each of pH 4-6 and 6-8) (3). Slices were
eluted into PBS, the eluates were dialyzed, and assayed for IL-1.
IL-1 Neutralization Assay.
￿
IL-1 or test sera at 10-20 U/ml were pre-incubated for 2-4 h
at 37°C with or without the indicated antibodies (1 mg/ml) in a final volume of 50 tl/well.
Thesamples were then assayed forIL-1 activity. Normal rabbit (NR) Ig was used as acontrol.
RNA Isolation andAnalysis.
￿
RNA was isolated by the guanidinium isothiocyanate/CsCI
method (13). Northern blots were made, baked, and prehybridized using standard proce-
dures (14). Hybridization was carried out for 48 h with 2 x 106 cpm/ml probe, and labeled
usingthe random oligomer primingreaction (15). Blotswere washed usingstandard method-
ology, with a final stringency of0.1 x SSC/0.1% SDS, at 55°C, and were exposed to Kodak
X-Omat AR film . Hybridization was quantitated by densitometry; the data are presented
as the ratio of IL-1 mRNA to 18S rRNA. RNA slot blots were prepared using a blotting
manifold (Schleicher & Schuell, Inc., Keene, NH) and processed in the same manner as the
Northern blots.
DNA Probes.
￿
The IL-la probe was the 1.7-kb Xho I insert of paIL-1; the IL-1/3 probe
was the 1.3-kb Pst I insert of poIL-1. Both probes were a gift of Dr. Yu-Chung Yang (Genetic
Institute, Cambridge, MA). The 18SrRNA probewaspXC-1, aratgenomic ribosomalprobe.
Results
TGPStimulates IL-1 Production by Human Leukocytes.
￿
Initially, 2.5 x 106 PBL were
allowed to adhere. The adherent cells were cultured for 24-48 h in 0.5 ml medium
containing 10o1o AB serum with 25 Ag/ml TGP (8, 10). IL-1 concentrations (n =
4) ranged from 130 to 566 U/culture with an average (mean ± SEM) of 299 ±
94 U/culture. IL-1 production by TGP-stimulated cells is dose dependent: 0.1 Fig/ml
TGP causing detectable production (46, 58, and 131 U/culture), with maximum
production (169 ± 76 U/culture; n = 5) obtained at 10-25 ug/ml. Similar levels
of IL-1 were produced whether PBL or adherent cells were cultured with TGP and
whether FCS, autologous, or AB serumwere added to the culture media. In serum-
free medium only about one-third as much IL-1 was produced by TGP-stimulated
cells as was produced in the presence of serum. It should be noted that TGP is not
mitogenic to thymocytes (10) and that the IL-1-like activity in these cultures is not
due to IL-2, since TGP does not stimulate IL-2 production (8).
Characterization of 7-UP-induced IL-1.
￿
IL-1 neutralization using antibodies specific
for IL-la and IL-10 suggested that both species of IL-1 were produced by TGP-
stimulated adherent cells (Fig. 1 b, A and B) or PBL (Fig. 1 b, CandD). Tworoughly
equalpeaks ofIL-1 activity with pIsof 5.3 and 7.0 were obtained when concentrated
supernatants of PBL cultured with TGP were analyzed by IEF (Fig. 1 a). The IL-1
with the acidic pI was neutralized by antibodies to IL-la and the second peak was
neutralized by antibodies to IL-1,(i (data not shown) . Twopeaks ofIL-1 activity wereJ
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FIGURE 1.
￿
IL-la and IL-l0 production by TGP-stimulated cells. (a) IEF ofpooled supernatants
from PBL cultured for 12-48 h with TGP (15 ug/ml). The slice number is indicated on the ab-
scissa and the pH and the ['H]TdR incorporated by thymocytes is shown on the Y-axis. (b) IL-1
neutralization by antibodies to: IL-1 (a + 0) (A), IL-la ([J), IL-10 (/), or with NRIg (x),
of supernatants from adherent cells (A and B), or PBL (C and D) from four individual donors
cultured for 24-48 h with TGP (10-15 Wg/ml). IL-1 activity in the absence ofantibodies was de-
fined as 100%.
also obtained when supernatants of adherent cells were analyzed by IEF; for these
the ratio of IL-lot to IL-1(3 was roughly 2:3 .
The molecular mass of the IL-1 was determined to be 14-15 kD by gel filtration
chromatography on a Sephacryl 5200 SF column. The IL-1 eluted from the column
showed an IEF pattern similar to that in Fig. 1 a.
Kinetics ofIL-1Activityin Cultures of TGP-stimulated Cells.
￿
PBL cultured with TGP
proliferate between days 5 and 10 of culture (8, 10). To determine whether the IL-1
production correlates with proliferation, supernatants from PBL or adherent cells
cultured with TGP for various times were assayed for IL-1 (Fig. 2). IL-1 activity
was present by 4 h ofculture, peaked between 16 and 24 h, and decreased thereafter.
FIGURE 2.
￿
Kinetics of IL-1 activity in superna-
tants of PBL (A) or adherent cells (p) cultured
with TGP (15,ug/ml) or media alone (x). Super-
natants were collected at the indicated times, and
their IL-1 activity was measured. This figure
represents six independent experiments, all of
which gave similar results.330
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A second peak of activity was observed between days 4 and 5 of culture (Fig . 2) .
Similar kinetics were observed with bothPBL and adherent cells cultured with TGP
(Fig . 2) .
Two Peaks ofIL-1 mRNA .
￿
To determine whether this secondary peak of IL-1 ac-
tivity was concomitant with an increase in the steady state level of IL-1 mRNA,
RNA isolated from TGP-stimulated PBL was subjected to Northern blot (Fig . 3
A-C) or slot blot (Fig . 3 D) analysis . IL-10mRNA was detectable by 1 h of culture
(Fig . 3 C) . The steady state level of the IL-lß mRNA peaked at -16 h (Fig . 3, A
and B), decreased, and then increased again on day 5 of culture (Fig . 3, A and B) .
Hybridization to RNA from PBL cultured with TGP for up to 9 d confirmed the
appearance of a second peak of IL-lß mRNA in TGP-treated cells (Fig . 3 D) .
FIGURE 3 .
￿
Analysis of IL-10 mRNA in PBL cultured with or without TGP (25,ug/ml) for the
times indicated on the x-axis . (A) Northern blot of pooled RNA from PBL of three volunteers
that were cultured with (T) or without (C) TGP for the indicated times . (B-D) Ratio of IL-10
mRNA to 18S rRNA in RNA of PBL cultured with (/) or without (x) TGP . Arbitrary units
were determined from densitometry scans of x-ray film of Northern blots (B and C) and a slot
blot (D). (B) Densitometry tracing of the Northern blot in (A) . (C) RNA from PBL of an in-
dividual donor stimulated with TGP for short periods of times. (D) Pooled RNA from PBL of
three donors, which were cultured for up to 9 d .FRANCUS ET AL.
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Discussion
In this study we show that TGP, a rutin-rich glycoprotein purified from tobacco
and present in tobacco smoke, induces human mononuclear cells to produce IL-1.
Two aspects of this response are of particular interest. First, about one-third of the
IL-1 secreted is IL-lcx, which contrasts with the preferential secretion of IL-10 by
humanleukocytes cultured with other inducers ofIL-1 (2), includingChlamydia tracho-
matis (Rothermal, C. D., J. Schachter, P. Lavrich, E. C. Lipsitz, and T. Francus,
manuscript submitted for publication). Second, theinitial peak of IL-1 activity occurs
by 24 h of culture and is followed by a second peak of IL-1 activity 4-6 d thereafter.
Analysis ofRNA from these cells shows that the second increase in IL-1 is concomi-
tant with increased steady state levels of IL-10 mRNA. Preliminary data suggest
a similar pattern of IL-Ix expression, although the steady state level of the IL-1a
mRNA is much lower. TGP has some unusual effects on the immune system. It
stimulates the proliferation of human T cells in an IL-2-independent manner (8).
TGP is a B cell mitogen in mice (10) and it preferentially elicits IgE production
(7). The polyphenol groups seem to play a regulatory role in the preferential IgE
response (7). Induction of both IL-lu and IL-10 by TGP supports the view that
TGP activates cells of the immune network via a different pathway than other B
or T cell mitogens.
Whether the second peak of IL-1 mRNA and of IL-1 activity in TGP-stimulated
cells is unique to this system is under study. The second peak could result from the
reactivation ofthe same cells or the stimulation of adifferent subpopulation of cells
by TGP, by the IL-1 (2), or other factors produced by TGP-stimulated cells. These
results suggest that the cells initially stimulated to make IL-1 do not become refrac-
tory to restimulation, and/or that a more quiescent cell population can ultimately
be stimulated. When taken in the context of the continuous exposure of the smoker
to TGP-like products, and the broad biological effects of IL-1, the role of IL-1 in
the pathology of cigarettte smoking should be considered. IL-1 enhances leukocyte
binding to human vascular endothelial cells, increases their procoagulant activity,
their production of plasminogen activator inhibitor, and the release of PAF (2) and
PDGF (6). Thus, IL-1 could initiate a cascade ofevents that bring about adecrease
in blood flow and an accumulation of leukocytes and platelets, resulting in clot for-
mation and vascular damage. In this respect, it is worth noting the recent studies
showing a decrease in the production of IL-1 and TNF by PBL of volunteers who
added w-3 polyunsaturated fatty acids to their diet (16). Since a low incidence of
cardiovascular and inflammatory diseases has been associated with diets including
w-3 fatty acids (reviewed in reference 16), the reduced production of IL-1 in these
volunteers is consistent with the hypothesis that IL-1 production in vivo plays a role
in the cardiovascular disease associated with cigarette smoking.
Summary
We have previously shown that tobacco glycoprotein (TGP), a polyphenol-rich
glycoprotein isolated from tobacco or from cigarettesmoke, affects theimmune system.
In this studywe show that TGP induces human PBLand adherent cells to produce
IL-laand IL-1/3. Two peaks ofIL-1 activity were observed; one at 18-24 h, the second
at 4-6 d after initiation of culture. A similar pattern was observed for the steady
state level of IL-1 mRNA . These data suggest that the production of IL-1 by cells33 2
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stimulated with TGP might be a factor in cardiovascular disease associated with
cigarette smoking.
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